A single arm phase II study of ADjuvant Endocrine therapy subcutaneous Pertuzumab and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive HER2-positive breast cancer (ADEPT)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Anatomic Stage I Hormone Receptor-positive, Her2-positive Breast Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. HER2-positive T1 histologically confirmed invasive carcinoma of the breast. Patients must have node-negative (N0) or micrometastases (N1mi) breast cancer according to the JCC 8th edition anatomic staging table.
    2. For unifocal disease,

You may not be eligible for this study if the following are true:

    1. Neoadjuvant or adjuvant chemotherapy for this breast cancer prior to enrollment is prohibited.
    2. Any of the following due to teratogenic potential of the study drugs: Pregnant women, ?Nursing women,? Women of childbearing potential who


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.